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Abstract
Background: The aim was to investigate whether mild kidney dysfunction and low-grade inflammation in post-
myocardial infarction patients are independently associated with markers of mental well-being (i.e. depressive
and apathy symptoms, and dispositional optimism).
Methods: In post-myocardial infarction patients, kidney function was assessed by estimated glomerular filtration
rate (eGFR) calculated from the combined CKD-EPI formula based on serum levels of both creatinine and cystatine
C. Systemic inflammation was assessed using high sensitivity C-reactive protein (hs-CRP) levels. The 15-item Geriatric
Depression Scale (GDS-15), the 3-item apathy subscale and the 4-item optimism questionnaire (4Q) were used to
measure mental well-being and were analyzed using linear multivariable regression analysis.
Results: Of the 2355 patients, mean age was 72.3 (range 63–84) years and 80.1% were men. After multivariable
adjustment, a poorer kidney function was associated with more depressive symptoms (β = -0.084, p < 0.001),
more apathy symptoms (β = -0.101, p < 0.001), and less dispositional optimism (β = 0.072, p = 0.002). Moreover,
higher levels of hs-CRP were associated with more depressive symptoms (β = 0.051, p = 0.013), more apathy
symptoms (β = 0.083, p < 0.001) and less dispositional optimism (β = -0.047 p = 0.024). Apathy showed the
strongest independent relation with both low eGFR and high hs-CRP.
Conclusions: In post-myocardial infarction patients, impaired kidney function and systemic inflammation showed
a stronger association with apathy than with depressive symptoms and dispositional optimism.
Keywords: Kidney dysfunction, Systemic inflammation, Apathy, Depressive symptoms, Dispositional optimism,
Myocardial infarction
Background
Depressive symptoms in coronary heart disease (CHD)
patients are associated with an increase in cardiac
morbidity and mortality [1]. The prevalence of major
depressive disorder (MDD) in post-myocardial infarc-
tion patients is estimated at about 20% [2]. CHD is also
associated with an increased occurrence of chronic
kidney disease (CKD) [3], which may further contribute
to the development of depressive symptoms [4–6]. It is
well established that end-stage renal disease (ESRD) is
associated with a poor quality of life and depressive
symptoms, whereas this has not been thoroughly inves-
tigated for earlier stages of CKD. Patients with ESRD
also have a prevalence of about 20% for MDD [7].
Moreover, as an inflammatory reaction is common in
patients with ESRD, it is hypothesized that inflamma-
tion partly links ESRD to depressive symptoms [8, 9].
Systemic low-grade inflammation is present in patients
with CKD, as well as in CHD, and may mediate the in-
creased risk of depressive symptoms and apathy [10–13].
In three large cross-sectional studies, including 3700
to ≥ 28,000 patients [14–16], those with severe CKD
(i.e. with an estimated glomerular filtration rate [eGFR]
<30 ml/min/1.73 m2) had more depressive symptoms
* Correspondence: heeresrick@gmail.com
1Department of Psychiatry, Leiden University Medical Center, Postbus 9600,
2300, RC, Leiden, Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Heeres et al. BMC Psychology  (2017) 5:1 
DOI 10.1186/s40359-016-0170-z
than those without CKD (eGFR ≥ 60 ml/min/1.73 m2).
However, in only one of those studies (that included pa-
tients with diabetes) did the increased risk of depressive
symptoms remain significant after adjustment for all
relevant covariates [15]. Whether or not less severe
forms of impaired kidney function (30 ml/min/1.73 m2
or higher) are associated with more depressive symp-
toms is still largely unknown. Moreover, the largest
study that analyzed the continuous relation between
eGFR and depressive symptoms found no significant
associations [14]. Moreover, we are aware of only two
studies on the association between CKD and depressive
symptoms in cohorts of cardiac patients. In 374 patients
suffering from congestive heart failure, Hedayati et al.
found that those with severe CKD scored significantly
higher on depressive symptoms [17]. In contrast, among
967 CHD patients, Odden et al. found no significant dif-
ference in depressive symptoms between patients with
and without CKD [18].
A low-grade pro-inflammatory state is common in pa-
tients with CHD, exemplified by higher levels of serum
C-reactive protein (CRP) [13]. A positive association be-
tween inflammatory markers and depressive symptoms
is also well established in persons without somatic illness
[19]. However, less is known about these associations in
CHD patients. Among three studies that included from
71 to almost 1000 CHD patients [20–22], only the
smaller study found a significantly increased CRP level
in depressed CHD patients [22], whereas the two larger
studies found no significant relation [20, 21]. In another
study, when examining the linear relation between in-
creasing CRP level and depressive symptoms, higher
levels of CRP showed a significant association with more
depressive symptoms; however, this association did not
persist after adjustment for covariates [23].
The association between depressive symptoms and
CHD has been called into question by recent cross-
sectional and prospective studies in community-dwelling
elderly [24–26]. Apathy, rather than depressive symp-
toms, was significantly associated with a higher inci-
dence of CHD and other cardiovascular diseases. Apathy
is a syndrome of primary motivational loss which mani-
fests itself in a decrease in goal-directed cognition,
emotion and behavior [27]. Two cross-sectional studies
(including 1810 and 3534 subjects, respectively) also
found that higher levels of CRP were significantly asso-
ciated with more apathy [25, 26]. However, two longitu-
dinal studies found no such association in 225 and
1015 elderly patients, respectively [28, 29].
The Alpha Omega Trial provided us with the opportun-
ity to perform a cross-sectional analysis of mental well-
being in post-myocardial infarction patients with a kidney
function that ranged from normal to non-dialysis-
dependent CKD stage 5. We aimed to investigate
whether mild kidney dysfunction and low-grade inflam-
mation were independently associated with markers of
mental well-being i.e. depressive symptoms, apathy
symptoms, and dispositional optimism. Dispositional
optimism is defined as generalized positive outcome
expectancies and a future orientation with trait-like
mental properties [30].
Whereas previous studies used only creatinine levels
to assess the eGFR, we included both creatinine and
cystatin-C (CysC) levels to more accurately estimate
kidney function [31], as well as high-sensitivity CRP
(hs-CRP) as a measure of systemic inflammation.
Methods
Patients
The Alpha Omega Trial was a multicenter, double-blind,
placebo-controlled trial conducted between 2002 and
2009 on the effect of low doses of n-3 fatty acids on car-
diovascular events, described in detail elsewhere [32, 33].
The cohort consisted of 4837 free-living Dutch post-
myocardial infarction patients aged 60–80 years, receiv-
ing state-of-the-art antihypertensive, antithrombotic
and lipid-modifying drug treatment at baseline. Patients
were randomly assigned to one of four trial margarines
and were followed-up for 40 months (ClinicalTrials.gov
no. NCT00127452). Blood samples were taken at base-
line and after 40 months in patients randomized before
August 2005 (i.e. 48% of the cohort, owing to financial
constraints). Mental well-being questionnaires were ad-
ministered at 40 months.
For the present cross-sectional study we used the 40-
month follow-up data of 2355 (48.7% of 4837) patients
who supplied blood samples and also completed the
mental well-being questionnaires at 40 months [33].
Assessment of psychological measures
Depressive symptoms were assessed using the 15-item
Geriatric Depression Scale (GDS-15) [34]. This self-
administered questionnaire contains 15 yes/no questions
and excludes certain somatic symptoms which might be
due to medical illness. Higher scores (range 0–15) indi-
cate more depressive symptoms during the past week.
The GDS-15 is a reliable and well-validated measure of
depressive symptoms in elderly medical patients [35].
For computation of the GDS-15 score, two missing
items were allowed and were subsequently imputed
with the mean of the remaining 13 or 14 items (n = 206
of 2355, 8.7%).
Apathy was assessed using the GDS apathy-3 subscale.
This is a subscale of the GDS-15 which consists of the
following three questions: “Have you dropped many of
your activities and interests?”, “Do you prefer to stay at
home, rather than going out and doing new things?”, and
“Do you feel full of energy?” Compared with the 14-item
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apathy scale [36], the GDS apathy-3 subscale has a sensi-
tivity of 69% and a specificity of 85% [24]. For computa-
tion of the GDS apathy-3 subscale, one missing item was
allowed and was subsequently imputed with the mean of
the remaining two items (n = 73 of 2355, 3.1%).
Dispositional optimism was assessed using the 4Q
which centers around a focus on the future and is more
closely related to life engagement, vitality, and feelings of
having a purpose in life. In the Netherlands, the 4Q was
used as part of a national ‘life situation’ survey by the
Central Bureau of Statistics in 1976 and 1982. The 4Q
consists of the following four items “I still expect much
from life,” “I do not look forward to the years to come,”
“My days seem to pass by slowly,” and “I am still full of
plans” (our translations). The response format was a 3-
point scale of frequency: “fully in agreement” (score, 0),
“partially in agreement” (score, 1), and “not in agree-
ment” (score, 2). The additional answer category “do not
know” was also coded as the midpoint (score, 1). The
scores of two questions needed to be reverse coded, so
that higher scores indicated greater optimism. Higher
scores (range 0–8) indicated higher dispositional opti-
mism. The 4Q shows moderate internal consistency and
has clinical predictive value for cardiovascular mortality
[37]. For computation of the 4Q score, one missing item
was allowed and was subsequently imputed with the
mean of the remaining 3 items (n = 21 of 2355, 0.9%).
Assessment of biological measures
Blood handling procedures for the Alpha Omega Trial
are described in detail elsewhere [38]. In brief, blood
samples were obtained at the patient’s home or at the
hospital, packaged in sealed envelopes and sent via
standard postal service to a central laboratory.
Serum creatinine and CysC were measured from
stored blood samples in a central laboratory [31]. Serum
creatinine was measured by the modified kinetic Jaffé
method (Dimension Vista 1500 Analyzer; Siemens). We
calibrated directly to the standard supplied by the manu-
facturer from the National Institute of Standards and
Technology Standard Reference Material, and a post-
calibration correction factor was applied [31]. Intra- and
inter-assay variations for low creatinine (mean = 0.8 mg/dl)
were 1.8 and 2.9%, respectively, and for high creatinine
(mean = 3.9 mg/dl) they were 0.8 and 2.2%, respectively.
Serum creatinine values < 0.6 mg/dl were unreliable (owing
to technical failure or analytical disturbance; n = 82) and,
therefore, not reported in accordance with the Standard
Operating Procedure of the central laboratory.
Serum CysC was measured by means of a particle-
enhanced immune nephelometric assay (NLatex Cystatin
C, Dimension Vista 1500 Analyzer; Siemens). We used
calibrators and assays of the same lot code, which was
stable (no downward drift). CysC was calibrated directly
using the standard supplied by the manufacturer (trace-
able to the International Federation of Clinical Chemistry
Working Group for Standardization of Serum Cystatin C)
[39]. The analytical measurement range of CysC was
0.23–8.00 mg/L. Intra- and inter-assay variations for low
CysC (mean = 1.00 mg/L) were 1.3 and 4.2%, respectively,
and for high CysC (mean = 1.75 mg/L) they were 2.9 and
2.8%, respectively.
We estimated GFR using the combined creatinine-
CysC-based Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equation from 2012, taking into
account age, sex, and race [31]. In addition, we used the
CysC-based eGFR from the CKD-EPI equation from
2012 as well as the creatinine based eGFR from the
CKD-EPI equation from 2009 separately [31].
Serum hs-CRP was measured in stored serum sam-
ples (Nephelometric, Deimension Vista 1500 analyzer,
Siemens). Intra- and inter-assay variation for low hs-
CRP (mean = 1.0 mg/l) was 2.1 and 1.6%, respectively,
and for high hs-CRP (mean = 2.8 mg/l) this was 2.0 and
2.4%, respectively.
Data collection
Patients were interviewed and physically examined by
trained research nurses at home or in the hospital. Infor-
mation on demographic variables (i.e., age, sex, ethnicity,
educational level), lifestyle habits (i.e. smoking status,
alcohol use, and physical activity), medication use and
medical history (i.e., time since myocardial infarction, and
history of stroke) were collected by self-administered
questionnaires, as previously described in detail [33].
Medication was coded according to the Anatomical
Therapeutic Chemical Classification System (ATC).
Anthropometric measures were measured, body mass
index (BMI) was computed (kg/m2) and blood pressure
was measured. Diabetes mellitus was considered present
in the case of a self-reported physician diagnosis, use of
antidiabetic drugs, and/or elevated blood glucose.
Data analysis
Patients were divided according to eGFR ≤ 60 or ≥ 60 ml/
min per 1.73 m2 and also divided according to the hs-CRP
level (<3 mg/l and ≥3 mg/l) based on the clinical cut-off
point of 3 mg/l. Patient characteristics are listed in Table 1;
data are presented as median (interquartile range),
mean (±SD), or number (percentage of the total), where
appropriate.
Four eGFR categories were defined based on eGFR; ≥
90, 60–89, 30–59, and < 30 ml/min/1.73 m2, using the
CKD classification as proposed by the National Kidney
Foundation-Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines [40]. Clinical cut-points of CRP for
risk of future cardiovascular events were used; levels <1,
1–3, 3–5, and ≥5 mg/L represent very low, low, mildly
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increased, and moderately to severely increased levels,
respectively [41].
Because plasma concentrations of hs-CRP showed a
positively skewed distribution, levels were loge trans-
formed before analyses to yield a normal distribution.
Mean GDS-15 and 4Q scores ± standard error as well as
median (25th and 75th percentiles [P25, P75]) were calcu-
lated per eGFR and hs-CRP category. The Pearson’s
correlation coefficient was used to assess the association
between the 12-item GDS depression score (excluding
the 3 apathy items) and the 3-item GDS apathy score, as
well as the association between the total GDS total score
and the 4Q optimism score. The Pearson’s correlation
coefficient was calculated between the original optimism
score and an optimism score in which all items with a
“don’t know” answer were imputed with the mean of
the remaining items. A correlation coefficient of 0.95
(P < 0.001) was found in the 463 participants with at
least one “don’t know” answer, suggesting that “don’t
know” coded as the midpoint was unlikely to have
distorted the total optimism score. Analysis of covari-
ance (ANCOVA) was used to determine significance
for linear trend over the four categories of eGFR and
CRP levels. All adjusted analyses were corrected for the
4 randomized groups (because, in the original trial, pa-
tients were treated during 40 months with either n-3
fatty acids or placebo) [33].
Models were specified for multivariable testing to ad-
just for possible confounders. Model 1 adjusted for age,
sex, level of education, and the 4 randomized treatment
groups; model 2 additionally adjusted for BMI, smoking
status, alcohol use, antidepressant use, time since myo-
cardial infarction, stroke and diabetes; model 3 was the
full model and additionally adjusted for the other pos-
sible predictor variables (either creatinine-CysC-based
eGFR or hs-CRP level) to determine the independent
association of eGFR and hs-CRP with depressive and
apathy symptoms, and dispositional optimism. More-
over, we included all three mental well-being parameters
(12-item GDS depression score (excluding the 3 apathy
Table 1 Characteristics of the cohort of 2355 post-myocardial infarction patients according to creatinine-cystatin C-based eGFR and
serum CRP level










Age, years 71.2 ± 5.04 75.4 ± 5.3 <0.001 72.0 ± 5.3 72.7 ± 5.6 0.004
Men, No. (%) 1465 (83.7%) 422 (69.8%) <0.001 1291 (82.5%) 596 (75.3%) <0.001
Higher education a, n (%) 767 (44.0%) 238 (39.7%) 0.064 715 (45.9%) 290 (36.9%) <0.001
Body mass indexb, kg/m2 27.6 ± 3.6 28.1 ± 4.1 0.003 27.3 ± 3.4 28.6 ± 4.15 <0.001
Physically activec, n (%) 389 (22.3%) 87 (14.5%) <0.001 340 (21.8%) 136 (17.3%) 0.010
Current smoker, n (%) 267 (15.3%) 83 (13.8%) 0.363 184 (11.8%) 166 (21.0%) <0.001
Alcohol use ≥1 glass/week, n (%) 1286 (73.6%) 360 (59.9%) <0.001 1135 (72.8%) 510 (64.8%) <0.001
Antidepressant use, n (%) 78 (4.5%) 40 (6.6%) 0.036 67 (4.3%) 51 (6.4%) 0.023
Time since myocardial infarction, years 4.5 ± 3.1 4.7 ± 3.4 0.110 4.5 ± 3.2 4.7 ± 3.2 0.117
Self-reported history of stroke, n (%) 94 (5.4%) 58 (9.7%) <0.001 84 (5.4%) 68 (8.7%) 0.003
Diabetesd, n (%) 93.1 (22.3%) 188 (31.1%) <0.001 375 (24.0%) 204 (25.8%) 0.334
Systolic blood pressure, mmHg 142.9 ± 20.5 141.6 ± 23.7 0.188 143.4 ± 20.9 140.9 ± 22.1 0.006
Use of cardiovascular medicatione, n (%)
Antithrombotic agents 1713 (97.9%) 584 (96.5%) 0.063 1529 (97.8%) 768 (97.1%) 0.322
Blood pressure lowering drugs 1729 (98.8%) 591 (97.7%) 0.051 1537 (98.3%) 783 (99.0%) 0.176
Statins 1553 (88.7%) 513 (84.8%) 0.011 1399 (89.5%) 667 (84.3%) <0.001
High-sensitivity C-reactive protein, mg/L 1.42 (0.71-3.15) 3.33 (1.27-6.91) <0.001 1.01 (0.61-1.72) 5.66 (4.04-8.83) <0.001
Serum creatininef, mg/dl 0.96 ± 0.18 1.54 ± 0.61 <0.001 1.05 ± 0.33 1.22 ± 0.56 <0.001
Serum cystatin C, mg/L 0.89 ± 0.13 1.41 ± 0.42 <0.001 0.96 ± 0.24 1.15 ± 0.42 <0.001
Data are presented as median (interquartile range), mean (± SD) or number (percentage of the total)
aDefined as higher vocational education, college or university
bBody mass index was calculated as weight in kilograms divided by height in meters squared
cDefined as ≥3 Metabolic Equivalent Tasks (MET) during >5 days/week
dDiabetes was considered to be present if a patient reported having received the diagnosis from a physician, was taking antidiabetic drugs, or had an elevated
plasma glucose level (≥126 mg/dl in the case of patients who had fasted more than 4 h or ≥200 mg/dl in the case of non-fasting patients)
eAntithrombotic agents ATC code B01. Blood pressure lowering drugs: ATC codes C02, C03, C07, C08 and C09. Statins: ATC code C10AA
fTo convert the values for creatinine to μmol/L, multiply by 88.40
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items), 3-item GDS apathy score and the 4Q optimism
score) into one statistical model as independent variables
with eGFR or hs-CRP as the dependent variables. Linear
associations were tested using univariate regression ana-
lysis. Analyses were stratified for gender, and gender ×
predictor interaction terms were added to the full model
3 to test whether associations showed a significant dif-
ference between women and men.
Two additional sensitivity analyses were performed in
which, first, we excluded all 221 participants with any
missing items on any of the mental well-being question-
naires and, second, we also excluded all 463 participants
with a “don’t know” answer on the 4Q as well as the 221
participants with any missing items, leaving 1723 partici-
pants available for the analyses.
All analyses were conducted using IBM SPSS statistics
20.0 (SPSS, Inc., Chicago, IL, USA).
Results
In the total group of 2355 patients, mean age was
72.3 years; 80.1% were men and 99.8% were Caucasian.
Of all patients, 1750 (74%) had an eGFR ≥ 60 ml/min/
1.73 m2. The remaining 605 (26%) patients with an
eGFR < 60 ml/min/1.73 m2 were more often female, less
physically active, used less alcohol, more often had dia-
betes, and had a higher mean level of hs-CRP than those
with an eGFR ≥ 60 ml/min/1.73 m2. There were 1564
(66%) patients with a low hs-CRP level of ≤ 3 mg/L; the
791 patients with a high hs-CRP level were more often
female, more often smoked, and used less alcohol than
those with low hs-CRP (Table 1).
The Pearson’s correlation coefficient showed that the
association between the apathy score and the 12-item
GDS depression score (excluding the 3 apathy items)
was only 0.42. The complete 15-item GDS total score
and the 4Q optimism score were inversely associated
with a correlation coefficient of -0.63.
Kidney function and mental well-being
In the fully adjusted model, categories with lower eGFR
showed a significant association with more depressive
symptoms. Patients with an eGFR < 60 ml/min/1.73 m2
had significantly more depressive symptoms (mean
GDS-15 score 2.70) than patients with an eGFR ≥ 60 ml/
min/1.73 m2 (mean GDS-15 score 1.80). Categories with
lower eGFR showed a significant association with more
apathy symptoms. Patients with an eGFR ≥ 90 ml/min/
1.73 m2 showed significantly less apathy than patients
with an eGFR of 60–89 ml/min/1.73 m2. Categories with
lower eGFR were also significantly associated with less
dispositional optimism (Table 2).
Likewise, linear regression analyses showed that a
lower level of eGFR was linearly associated with more
depressive symptoms (β = -0.084, p < 0.001) and with less
dispositional optimism (β = 0.072, p = 0.002; Table 3).
The association between a lower level of eGFR and more
apathy symptoms was stronger (β = -0.101; p < 0.001).
All these associations persisted after additional adjust-
ment for hsCRP. Interaction terms showed that relations
were similar in women and men (p > 0.30, for all three
interaction terms). When including all three mental
well-being parameters into one statistical model as inde-
pendent variables with eGFR as the dependent variable,
apathy (β = -0.066, p = 0.001) was the only significant
correlate, whereas dispositional optimism (p = 0.12) and
the 12-item GDS depression score (p = 0.99) were no
longer significant. Moreover, when we excluded the 48
participants with a eGFR < 30 ml/min/1.73 m2 from the
analyses, the eGFR was still inversely associated with
apathy (β = -0.054, p = 0.01), independently from CRP
and all other covariates.
C-reactive protein and mental well-being
In the fully adjusted model, categories of higher hs-CRP
serum level showed a significant association with more
depressive symptoms, more apathy symptoms and less
dispositional optimism (Table 2). Linear regression
analysis also showed that a higher level of hs-CRP was
significantly associated with more depressive symptoms
(β = 0.051; p = 0.013) more apathy symptoms (β = 0.083;
p < 0.001) and less dispositional optimism (β = -0.047;
p = 0.024). However, after additional adjustment for the
eGFR, only the association with apathy remained signifi-
cant (β = -0.065; p = 0.002). In Fig. 1, the adjusted relation-
ship with categories of hs-CRP seem to depict a threshold
effect for the CRP level of ≥ 7. Moreover, when including
all three mental well-being parameters into one statistical
model as independent variables with the log-transformed
CRP level as the dependent variable, apathy (β = 0.082,
p < 0.001) was the only significant correlate, whereas
dispositional optimism (p = 0.40) and the 12-item GDS
depression score (p = 0.36) were not.
When testing for interaction, the interaction term for
gender × hs-CRP was significant for depression (β = 0.129,
p = 0.008), not significant for apathy (β = 0.076, p = 0.12),
and of borderline significance for optimism (β = -0.088,
p = 0.074). In subsequent stratified analyses, associations
with depressive symptoms (β = 0.064, p = 0.007), apathy
symptoms (β = 0.079, p = 0.001) and optimism (β = -0.059
p = 0.014) were stronger in men than in women.
Sensitivity analysis in 2134 and 1723 participants (i.e.
excluding those with missing values and “don’t know”
answer category) showed that the relationship between
eGFR and CRP on the one hand, and depressive/apathy
symptoms and optimism on the other, were hardly
affected. In particular, there was no attenuation as, in
the adjusted model, the relationship with CRP increased
in strength in the sample of 1723 participants.
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Discussion
The present results show that kidney dysfunction
(reflected by a lower eGFR) and systemic inflammation
(reflected by a higher hs-CRP level) were independently
associated with apathy in post-myocardial infarction pa-
tients. The associations with depressive symptoms and
dispositional optimism were less robust. Kidney dysfunc-
tion showed a linear and somewhat stronger association
for apathy than for systemic inflammation, for which
there seemed to be a threshold value of 7 mg/L.
We are not aware of previous studies that assessed the
relation between kidney dysfunction and apathy symp-
toms in a large cohort. Nevertheless, our findings are in
line with others reporting that patients with an eGFR <
30 ml/min/1.73 m2 had more depressive symptoms than
patients with an eGFR ≥ 90 ml/min/1.73 m2 [14–16]. We
Table 2 Categories of creatinine-cystatin C-based eGFR and serum level CRP in relation to depressive and apathy symptoms, and











Test statistic P-value for trend
Depressive symptoms:
Median (P25, P75) 1 (0 – 2) 1 (0 – 3) 2 (1 – 4) 2 (1 – 4)
crude 1.54 (SE 0.08)a 1.92 (SE 0.06)b 2.68 (SE 0.12)c 3.12 (SE 0.41)c F(1, 2351) = 80.6 <0.001
model 1 1.72 (SE 0.10)a 1.94 (SE 0.06)a 2.47 (SE 0.10)b 2.90 (SE 0.31)b F(1, 2335) = 31.4 <0.001
model 2 1.79 (SE 0.10)a 1.95 (SE 0.06)a 2.34 (SE 0.10)b 2.67 (SE 0.31)b F(1, 2280) = 17.4 <0.001
Apathy subscale:
Median (P25, P75) 0 (0 – 1) 1 (0 – 2) 1 (0 – 2) 2 (1 – 2.5)
crude 0.74 (SE 0.04)a 0.97 (SE 0.03)b 1.29 (SE 0.04)c 1.64 (SE 0.14)d F(1, 2351) = 108.5 <0.001
model 1 0.85 (SE 0.04)a 0.98 (SE 0.03)b 1.18 (SE 0.04)c 1.47 (SE 0.14)d F(1, 2335) = 36.1 <0.001
model 2 0.87 (SE 0.04)a 0.99 (SE 0.03)b 1.12 (SE 0.04)c 1.38 (SE 0.13)c F(1, 2280) = 20.4 <0.001
Dispositional optimism:
Median (P25, P75) 7 (6 – 8) 7 (6 – 8) 6 (5 – 7) 6 (4 – 7)
crude 6.71 (SE 0.06)a 6.38 (SE 0.04)b 5.82 (SE 0.08)c 5.59 (SE 0.25)c F(1, 2351) = 94.7 <0.001
model 1 6.49 (SE 0.07)a 6.36 (SE 0.04)a 6.04 (SE 0.07)b 5.91 (SE 0.22)b F(1, 2335) = 21.6 <0.001
model 2 6.46 (SE 0.07) 6.35 (SE 0.04) 6.08 (SE 0.07) 6.01 (SE 0.22) F(1, 2280) = 14.2 <0.001










Median (P25, P75) 1 (0 – 3) 1 (0 – 3) 1 (0 – 3) 2 (1 – 3.7)
crude 1.86 (SE 0.08)a 1.87 (SE 0.07)a 2.15 (SE 0.13)a 2.55 (SE 0.12)b F(1, 2351) = 28,34 <0.001
model 1 1.92 (SE 0.08)a 1.88 (SE 0.08)a 2.12 (SE 0.12)a 2.45 (SE 0.11)b F (1, 2351) = 17.0 <0.001
model 2 1.97 (SE 0.08) 1.89 (SE 0.08) 2.07 (SE 0.12) 2.30 (SE 0.10) F(1, 2280) = 6.7 0.010
Apathy subscale:
Median (P25, P75) 1 (0 – 1,1) 1 (0 – 2) 1 (0 – 2) 1 (0 – 2)
crude 0.88 (SE 0.03)a 0.98 (SE 0.04)b 1.05 (SE 0.05)b 1.26 (SE 0.05)c F(1, 2351) = 42.8 <0.001
Model 1 0.90 (SE 0.04)a 0.99 (SE 0.03)a 1.04 (SE 0.05)a 1.21 (SE 0.05)b F (1, 2335) = 27.6 <0.001
model 2 0.93 (SE 0.04)a 0.99 (SE 0.03)a 1.01 (SE 0.05)a 1.16 (SE 0.05)b F (1, 2280) = 14.4 <0.001
Dispositional optimism:
Median (P25, P75) 7 (6 – 8) 7 (6 – 8) 6 (5 – 8) 6 (5 – 7)
crude 6.46 (SE 0.06)a 6.39 (SE 0.06)a 6.16 (SE 0.10)b 6.02 (SE 0.08)b F(1, 2351) = 24.9 <0.001
model 1 6.40 (SE 0.06) 6.38 (SE 0.06) 6.17 (SE 0.09) 6.10 (SE 0.07) F (1, 2335) = 12.8 <0.001
model 2 6.37 (SE 0.06) 6.38 (SE 0.06) 6.18 (SE 0.09) 6.16 (SE 0.07) F (1, 2280) = 6.8 0.009
Data are reported as (adjusted) mean and standard errors (SE)
Analysis of covariance (ANCOVA) was used to determine significance for linear trend over the 4 categories of eGFR and CRP levels
Model 1: adjusted for age, sex, education, and 4 randomized groups (using 3 dummy variables)
Model 2: additionally adjusted for body mass index, smoking status, alcohol use, antidepressant use, statin use, time since myocardial infarction, stroke
and diabetes
abcd Superscript letters that are dissimilar indicate significant differences in post-hoc tests
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extended these findings by showing that an increase in
depressive symptoms was already present in patients
with an eGFR < 60 ml/min/1.73 m2 compared to those
with a better eGFR. Low apathy was found within the
normal range of kidney function. On the other hand,
our results are in contrast to those of the only other
large study on CHD patients (n = 967) that did not find
more depressive symptoms in patients with an eGFR <
60 ml/min/1.73 m2 compared to those with an eGFR
of ≥ 60 ml/min/1.73 m2 [18]. However, this latter study
dichotomized kidney function at < 60 ml/min/1.73 m2
which reduced the statistical power, and did not include
CysC levels or apathy in their analyses. A study in a gen-
eral population sample of over 28,000 individuals showed
an inverse, linear trend relation between kidney function
and depression, which did not persist in the multivariable
model [14]; however, in that study depression was mea-
sured using the 4-item Center for Epidemiologic Studies
Depression Scale during a telephone interview and, again,
neither CysC levels nor apathy were assessed. We have ex-
tended these findings by showing a linear trend relation
between eGFR and depressive symptoms, which was
strongest for the apathy subscale.
Several mechanisms could be involved in the relation
between kidney dysfunction and apathy. For example,
the vascular apathy hypothesis is suggested to underlie
the relation between vascular disease and apathy symp-
toms [24]. Atherosclerosis may have caused renal vascular
disease resulting in poorer eGFR as well as cerebrovascular
disease causing brain ischemia which may result in apathy.
The accumulation of uremic toxins causes encephalopathy
in patients with kidney failure [42]. In patients with less
severe kidney impairment, the neurotoxic effect of the ac-
cumulation of uremic toxins might have resulted in less
extreme symptoms of apathy. Furthermore, anemia is a
well-known complication of chronic kidney disease and
could be part of the causal pathway to apathy. Also, apathy
symptoms might overlap with other symptoms that occur
Table 3 Associations of creatinine-cystatin C-based eGFR and serum CRP level with depressive and apathy symptoms, and dispositional
optimism in 2355 post-myocardial infarction patients
Depressive symptoms
Crude Model 1 Model 2 Model 3
Creatinine-cystatin C-based eGFR -0.181 -0.116 -0.084 -0.074
t = –8.904 t = -5.118 t = -3.691 t = -3.195
p <0.001 p <0.001 p <0.001 p = 0.001
C-reactive protein levels 0.106 0.082 0.051 0.035
t = 5.171 t = 4.017 t = 2.476 t = 1.650
p <0.001 p <0.001 p = 0.013 p = 0.099
Apathy subscale
Crude Model 1 Model 2 Model 3
Creatinine-cystatin C-based eGFR -0.219 -0.135 -0.101 -0.084
t = -10.879 t = -6.002 t = -4.440 t = -3.598
p <0.001 p <0.001 p <0.001 p <0.001
C-reactive protein levels 0.137 0.110 0.083 0.065
t = 6.696 t = 5.479 t = 3.999 t = 3.039
p <0.001 p <0.001 p <0.001 p = 0.002
Dispositional optimism
Crude Model 1 Model 2 Model 3
Creatinine-cystatin C-based eGFR 0.194 0.089 0.072 0.063
t = 9.613 t = 3.979 t = 3.152 t = 2.693
p <0.001 p <0.001 p = 0.002 p = 0.007
C-reactive protein levels -0.094 -0.065 -0.047 -0.033
t = -4.585 t = -3.244 t = -2.258 t = -1.556
p <0.001 p = 0.001 p = 0.024 p = 0.12
Data are beta-coefficients (p-value) after linear regression analysis
CRP values were naturally log transformed before analysis because of a positively skewed distribution
Model 1: adjusted for age, sex, education, and 4 randomized groups (using 3 dummy variables)
Model 2: additionally adjusted for body mass index, smoking status, alcohol use, antidepressant use, statin use, time since myocardial infarction, stroke, and diabetes
Model 3: full model, additionally adjusted for the other possible predictors (Creatinine-cystatin C-based eGFR, or CRP levels)
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in patients with kidney dysfunction. For example, fatigue
shows some similarity with apathy and is one of the most
frequently mentioned symptoms in patients with severe
kidney dysfunction [43]. However, most studies on the re-
lation between fatigue and psychological factors focused
on depression and anxiety, but did not assess apathy.
Finally, a third factor, related to aging, may underlie both
apathy, inflammation and kidney dysfunction.
Earlier studies in CHD patients found no association
between CRP levels and depressive symptoms [20, 23, 44].
However, the use of statins (and possibly beta-blockers
and anti-depressants) may have reduced the inflammatory
state [45–47] and thereby obscured the relation between
CRP and depressive symptoms. In our study, however, an
even higher proportion of patients used statins (87.7%)
than in these latter studies; moreover, our study sample
was larger than that of earlier studies [20, 23, 44]. Our
findings are in line with the results of a large meta-ana-
lysis which also found that higher CRP levels were asso-
ciated with more depressive symptoms in healthy
individuals [19]. Also, for CRP levels we found that the
strongest association was with the apathy subscale.
Eurlings et al. found a concomitant relation between in-
flammation and apathy symptoms, and suggested that
apathy symptoms may be part of sickness behavior, which
can be described as a motivational state that reorganizes
the organism’s priorities to cope with systemic inflamma-
tion and infectious disease [29]. Kidney dysfunction may
have caused a higher systemic inflammatory state [8]
which, in turn, resulted in more apathy. However, this hy-
pothesis was only partly supported by our results which
show that the relation between eGFR and apathy symp-
toms is largely independent of CRP levels.
As opposed to depressive symptoms, optimism has been
associated with better health outcomes (such as survival)
in CHD patients and the general population [48–51]. Both
behavioral (e.g. healthy diet, physical activity, and non-
smoking) and biological pathways have been suggested as
mechanistic explanations. In CHD patients we found a
significant relation between eGFR and dispositional opti-
mism, and an inverse relation between CRP levels and
dispositional optimism. Other studies found no relation
between CRP and optimism or other measures of positive
affect, but did find an inverse relation with other markers
of inflammation, such as interleukin 6 (IL-6) and tumor
necrosis factor alpha (TNF-α) [52–54].
Some limitations of the present study need to be
addressed. First, because psychological measures were
assessed at 40 months only, we were unable to address
potential temporal relations. Second, because our cohort
consisted of post-myocardial infarction patients, the re-
sults cannot be extrapolated to other populations. Third,
depressive symptoms were assessed using a question-
naire with 15 relatively crude ‘yes/no’ answer categories.
Fourth, because we lacked information on proteinuria or
hematuria we could not distinguish between the pres-
ence or absence of chronic kidney disease in patients
with an eGFR of 60–89 ml/min/1.73 m2.
However, our study also has several strengths. The study
had a large enough sample size to detect small but signifi-
cant effects. Moreover, we used the combined creatinine-
CysC-based CKD-EPI equation to estimate the eGFR,
which is considered more accurate than creatinine-based
eGFR [31]. Also, use of the GDS-15 to assess depressive
symptoms excluded certain somatic symptoms which
might be due to medical illness in elderly medical patients
Fig. 1 Associations of the creatinine-cystatin C-based eGFR and serum CRP levels with apathy in 2355 post-myocardial infarction patients. Mean
serum eGFR and CRP levels are shown with error bars representing standard errors (SE), adjusted for age, sex, education, body mass index,
smoking status, alcohol use, antidepressant use, statin use, time since myocardial infarction, stroke, and diabetes. The box sizes represent the
relative number of patients
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[35]. Finally, it has been shown in cardiac patients that,
compared with the Beck Depression Inventory (BDI) I and
II, the GDS was better able to differentiate between those
who are depressed and those who are not depressed [55].
Conclusion
In conclusion, the present study shows a significant in-
dependent association between kidney dysfunction and
apathy in post-myocardial infarction patients. This as-
sociation was already apparent within the mild kidney
dysfunction range. This implies that, at the population
level, the impact of kidney dysfunction on mental well-
being may be large, since we found that 26% of post-
myocardial patients suffer from kidney dysfunction
(eGFR <60 ml/min/1.73 m2).
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